Abbvie Inc. vs Exelixis Inc
ABBV vs EXEL — side-by-side comparison from reported financials. ABBV leads 3, EXEL leads 5 of 8 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Exelixis Inc
EXEL · Healthcare
$60.62+2.71%Mixed
| Metric | ABBV | EXEL |
|---|---|---|
| Price | $276.43 | $60.62 |
| Market cap | $488B | $15.0B |
| Revenue (TTM) | $64.4B | $2.44B |
| Revenue growth | +1.8% | +12.9% |
| Net margin | 9.8% | 35.3% |
| Free cash flow | $18.2B | $1.17B |
| Net cash (debt) | ($56.2B) | — |
| 1-year price return | +19.8% | +57.2% |
| P/E | 77.4 | 17.2 |
| P/E vs own history (cheap-side %) | 23% | 81% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 42% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 57,000 | 1,077 |
Full résumé-style profiles: ABBV CV · EXEL CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.